Boston Scientific Co. (NYSE:BSX) Given Consensus Recommendation of “Buy” by Brokerages
Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating,
GlobalData on MSN3d
Farapulse boosts Boston Scientific’s Q4 electrophysiology sales by 172%Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating ...
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...
Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
Scientific American is part of Springer Nature, which owns or has commercial relations with thousands of scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback